PRO 08 - The Journey of the Unknown Primary in the HPV Era: Evaluation, Treatment, Surveillance and Management of Oligometastatic Disease
MODERATOR(S)
Virginia Diavolitsis, MD - Riverside Radiation Oncology Inc.
session DESCRIPTION
Management of unknown primary head and neck squamous cell carcinomas has evolved as the incidence of p16 positive disease among head and neck cancer patients has increased. This session will discuss the diagnostic steps to identify a primary site and treatment of patients where primary is and is not identified. We will also discuss post-treatment surveillance of p16 positive patients including the role of TTMV-HPV DNA as a surveillance tool. Finally, we will discuss management options for patients with oligometastatic disease.
learning objectives
- Explain the steps in evaluation of a patient with an unknown primary p16 positive head and neck squamous cell carcinoma and management of patients where primary site is not identified.
- Discuss the role of TTMV-HPV DNA as a surveillance tool for patients with p16 positive head and neck squamous cell carcinoma.
- Describe management options for patients with oligometastatic p16 positive head and neck squamous cell carcinoma.
Credits
| AMA PRA Category 1 Credits: | 1.25 |
| CAMPEP Credits: | 1.25 |
| MDCB Credits: | 1.25 |
Presentations
-
05:00pm - 05:02pm PTSpeaker: Virginia Diavolitsis, MD - Riverside Radiation Oncology Inc., Columbus
-
05:02pm - 05:22pm PTSpeaker: Jessica Lee, MD - Mid-Atlantic Permanente Medical Group, DC Metro Area
-
05:22pm - 05:42pm PTSpeaker: Edina Wang, MD - Duke University Medical Center, Durham
-
05:42pm - 06:02pm PTSpeaker: Musaddiq Awan, MD - Medical College of Wisconsin, Milwaukee
-
06:02pm - 06:15pm PTSpeaker: Virginia Diavolitsis, MD - Riverside Radiation Oncology Inc., Columbus